BRPI0512891A - composto e um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, métodos de inibir a quinase 1 do ponto de verificação em uma célula, de sensibilizar células em um indivìduo que passa por um tratamento quimioterapêutico ou radioterapêutico para uma condição médica e de inibir a proliferação de célula aberrante, uso de um composto, e artigo de fabricação para o uso farmacêutico em humano - Google Patents
composto e um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, métodos de inibir a quinase 1 do ponto de verificação em uma célula, de sensibilizar células em um indivìduo que passa por um tratamento quimioterapêutico ou radioterapêutico para uma condição médica e de inibir a proliferação de célula aberrante, uso de um composto, e artigo de fabricação para o uso farmacêutico em humanoInfo
- Publication number
- BRPI0512891A BRPI0512891A BRPI0512891-9A BRPI0512891A BRPI0512891A BR PI0512891 A BRPI0512891 A BR PI0512891A BR PI0512891 A BRPI0512891 A BR PI0512891A BR PI0512891 A BRPI0512891 A BR PI0512891A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- inhibiting
- methods
- solvate
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000002401 inhibitory effect Effects 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000004663 cell proliferation Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 230000001235 sensitizing effect Effects 0.000 title abstract 2
- 239000012453 solvate Substances 0.000 title abstract 2
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 title 1
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 title 1
- 230000001594 aberrant effect Effects 0.000 title 1
- 230000000973 chemotherapeutic effect Effects 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 230000003439 radiotherapeutic effect Effects 0.000 title 1
- 230000004543 DNA replication Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000005778 DNA damage Effects 0.000 abstract 1
- 231100000277 DNA damage Toxicity 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000032823 cell division Effects 0.000 abstract 1
- 230000024321 chromosome segregation Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 150000003672 ureas Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
COMPOSTO E UM SAL OU PRó-DROGA OU SOLVATO FARMACEUTICAMENTE ACEITáVEL DO MESMO, COMPOSIçãO, MéTODOS DE INIBIR A QUINASE 1 DO PONTO DE VERIFICAçãO EM UMA CéLULA, DE SENSIBILIZAR CéLULAS EM UM INDIVìDUO QUE PASSA POR UM TRATAMENTO QUIMIOTERAPêUTICO OU RADIOTERAPêUTICO PARA UMA CONDIçãO MéDICA E DE INIBIR A PROLIFERAçãO DE CéLULA ABERRANTE, USO DE UM COMPOSTO, E, ARTIGO DE FABRICAçãO PARA O USO FARMACêUTICO EM HUMANO Compostos de uréia substituídos úteis no tratamento de doenças e condições relacionadas com o dano ao DNA ou lesões na replicação do DNA são divulgados. Métodos de fabricar os compostos e seu uso como agentes terapêuticos, por exemplo, no tratamento de câncer e outras doenças caracterizadas pelos defeitos na replicação do DNA, segregação de cromossoma ou divisão celular também são divulgados.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58529204P | 2004-07-02 | 2004-07-02 | |
| PCT/US2005/023554 WO2006014359A2 (en) | 2004-07-02 | 2005-07-01 | Compounds useful for inhibiting chk1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0512891A true BRPI0512891A (pt) | 2008-04-15 |
Family
ID=35515699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0512891-9A BRPI0512891A (pt) | 2004-07-02 | 2005-07-01 | composto e um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, métodos de inibir a quinase 1 do ponto de verificação em uma célula, de sensibilizar células em um indivìduo que passa por um tratamento quimioterapêutico ou radioterapêutico para uma condição médica e de inibir a proliferação de célula aberrante, uso de um composto, e artigo de fabricação para o uso farmacêutico em humano |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7560462B2 (pt) |
| EP (1) | EP1768977A2 (pt) |
| JP (1) | JP2008505112A (pt) |
| KR (1) | KR20070043996A (pt) |
| CN (1) | CN101010316A (pt) |
| AU (1) | AU2005270102A1 (pt) |
| BR (1) | BRPI0512891A (pt) |
| CA (1) | CA2573063A1 (pt) |
| MX (1) | MX2007000265A (pt) |
| WO (1) | WO2006014359A2 (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004089296A2 (en) | 2003-04-03 | 2004-10-21 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| EP1765311A4 (en) | 2004-03-16 | 2009-04-29 | Univ California | REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS |
| EP1778648A2 (en) * | 2004-08-19 | 2007-05-02 | ICOS Corporation | Compounds useful for inhibiting chk1 |
| WO2006045119A2 (en) | 2004-10-20 | 2006-04-27 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| AR059826A1 (es) | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| EP2066642A1 (en) * | 2006-09-25 | 2009-06-10 | Arete Therapeutics, INC. | Soluble epoxide hydrolase inhibitors |
| EP2190429B1 (en) * | 2007-09-10 | 2016-04-20 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| EP2070929A1 (en) * | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| EP2528604B1 (en) | 2010-01-29 | 2017-11-22 | The Regents of the University of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| GB201119799D0 (en) | 2011-11-16 | 2011-12-28 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| US20160030384A1 (en) | 2013-04-09 | 2016-02-04 | Boston Biomedical, Inc. | 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer |
| AU2014293013A1 (en) | 2013-07-26 | 2016-03-17 | Race Oncology Ltd. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| DK3169671T3 (da) * | 2014-07-17 | 2019-09-23 | Sunshine Lake Pharma Co Ltd | 1-(5-(tert.-butyl)isoxazol-3-yl)-3-(4-((phenyl)ethynyl)phenyl)ureaderivater og relaterede forbindelser som flt3-inhibitorer til behandling af kræft |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| WO2017016523A1 (zh) * | 2015-07-30 | 2017-02-02 | 正大天晴药业集团股份有限公司 | 靶向idh2突变的抗肿瘤化合物及其使用方法 |
| CA3013514C (en) | 2016-02-04 | 2021-11-23 | Pharmaengine, Inc. | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
| CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| KR20190130621A (ko) | 2017-03-31 | 2019-11-22 | 시애틀 지네틱스, 인크. | Chk1 저해제와 wee1 저해제의 조합물 |
| JP2020520923A (ja) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル， インコーポレイテッド | がんを処置するための方法 |
| CN112457306A (zh) | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| WO2021119236A1 (en) | 2019-12-10 | 2021-06-17 | Seagen Inc. | Preparation of a chk1 inhibitor compound |
| GB202107924D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | A pharmaceutical salt |
| GB202107932D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | Preparation of a CHK1 Inhibitor Compound |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01163723A (ja) * | 1987-12-21 | 1989-06-28 | Nippon Telegr & Teleph Corp <Ntt> | 有機非線形光学材料 |
| ATE291011T1 (de) * | 1997-12-22 | 2005-04-15 | Bayer Pharmaceuticals Corp | Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen |
| GB9823873D0 (en) * | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| US20040034038A1 (en) * | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
-
2005
- 2005-07-01 AU AU2005270102A patent/AU2005270102A1/en not_active Abandoned
- 2005-07-01 JP JP2007519487A patent/JP2008505112A/ja active Pending
- 2005-07-01 EP EP05791683A patent/EP1768977A2/en not_active Withdrawn
- 2005-07-01 MX MX2007000265A patent/MX2007000265A/es not_active Application Discontinuation
- 2005-07-01 CA CA002573063A patent/CA2573063A1/en not_active Abandoned
- 2005-07-01 BR BRPI0512891-9A patent/BRPI0512891A/pt not_active IP Right Cessation
- 2005-07-01 KR KR1020077002555A patent/KR20070043996A/ko not_active Withdrawn
- 2005-07-01 CN CNA2005800294061A patent/CN101010316A/zh active Pending
- 2005-07-01 US US11/630,626 patent/US7560462B2/en not_active Expired - Fee Related
- 2005-07-01 WO PCT/US2005/023554 patent/WO2006014359A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US7560462B2 (en) | 2009-07-14 |
| US20080214573A1 (en) | 2008-09-04 |
| JP2008505112A (ja) | 2008-02-21 |
| CA2573063A1 (en) | 2006-02-09 |
| WO2006014359A3 (en) | 2007-01-11 |
| AU2005270102A1 (en) | 2006-02-09 |
| EP1768977A2 (en) | 2007-04-04 |
| KR20070043996A (ko) | 2007-04-26 |
| MX2007000265A (es) | 2007-07-20 |
| CN101010316A (zh) | 2007-08-01 |
| WO2006014359A2 (en) | 2006-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Santo et al. | Targeting cyclin-dependent kinases and cell cycle progression in human cancers | |
| Kaminskyy et al. | Antifibrotic and anticancer action of 5-ene amino/iminothiazolidinones | |
| EP3356359B1 (en) | Inhibitors of kras g12c mutant proteins | |
| Wang et al. | HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy | |
| ES2826443T3 (es) | Inhibidores de proteínas mutantes KRAS G12C | |
| RU2659786C2 (ru) | 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения | |
| NO20055496L (no) | Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer | |
| BRPI0515482A (pt) | derivados heterocìclicos e seus usos como agentes terapêuticos | |
| BR112014015720A2 (pt) | derivados de tieno[3,2-d]pirimidina que têm atividade inibidora de proteinas quinases | |
| WO2007113558A8 (en) | Quinazolinone derivatives having b-raf inhibitory activity | |
| US11667640B2 (en) | Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells | |
| WO2007071963A3 (en) | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents | |
| UY28990A1 (es) | Nuevos derivados de benceno 1, 3-amino carbonilo como inhibidores de b-raf, composiciones farmacéuticas que los contienen, procesos de preparación y uso. | |
| BRPI0515488A (pt) | derivados de heterocìclicos e seu uso como agentes terapêuticos | |
| ECSP13012852A (es) | Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a. | |
| BRPI0613570A8 (pt) | composto ou um sal do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar doenças mediadas por glk, e, processo para a preparação de um composto. | |
| AU2022205218A1 (en) | Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast | |
| SI2903616T1 (en) | The use of masitinib in combination with gemcitabine for the treatment of a subgroup of patients suffering from foot-and-mouth disease | |
| BR112019006742A2 (pt) | composições de aminoácido e usos das mesmas | |
| BR112021013362A2 (pt) | Agentes rnai para inibição da expressão de hif-2 alfa (epas1), suas composições e métodos de uso | |
| CA3185209A1 (en) | Gas41 inhibitors and methods of use thereof | |
| Qian et al. | The combination of thioxodihydroquinazolinones and platinum drugs reverses platinum resistance in tumor cells by inducing mitochondrial apoptosis independent of Bax and Bak | |
| BRPI0512593A (pt) | composto ou um sal ou pró-droga ou solvato farmaceuticamente aceitável do mesmo, composição, e, métodos de inibir a quinase 1 de ponto de verificação em uma célula, de sensibilizar células em um indivìduo e de inibir a proliferação de célula aberrante | |
| WO2024118830A1 (en) | Atropisomers of mat2a inhibitors | |
| BRPI0409683A (pt) | 5-hidroxiindóis com grupos n-óxido e seu emprego como agentes terapêuticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |